花旗发表研报指，再鼎医药(ZLAB.US) 旗下药物“Vyvgart”录3,000万美元(下同)销售额，符合市场预期，但略低于花旗预计的3,130万美元。鉴于中国预计于年中更新全国全身性重症肌无力症(gMG)指南，并为今年下半年提供顺风，Vyvgart应大幅推动再鼎医药2025财年收入指引5,600万至5,900万元。
花旗表示，现时预计Vyvgart在2025财年的销售额约1.75亿元，到2030财年将达到约7.72亿元的高峰。该行亦相信，今年的渠道数据、Vygart增长、越来越接近2026年KarXT推出的前景，应能重新激发投资者对该股的情绪。
花旗将再鼎医药美股目标价由70美元轻微上调至71美元，给予“买入”评级。(js/a)(美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.